{"title":"Breast Cancer","description":null,"products":[{"product_id":"phocrizo-250-crizotinib","title":"Parcini 100 (Palbociclib)","description":"\u003cp\u003ePalbociclib is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4\/6 inhibitor to be approved as a cancer therapy.\u003c\/p\u003e\n\n\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003e\nPalbociclib is used in combination with anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor–positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in women who have experienced menopause (change of life; end of monthly menstrual periods) or in men. Palbociclib is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor–positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in people who have been treated with an antiestrogen medication such as tamoxifen (Nolvadex). Palbociclib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eHow should this medicine be used?\u003cbr\u003e\nPalbociclib comes as a capsule to take by mouth. It is usually taken with food once daily for the first 21 days of a 28-day cycle. Your doctor will decide how many times you should repeat this cycle. Take palbociclib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take palbociclib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\n\n\u003cp\u003eSwallow the capsules whole; do not open, chew, or crush them. Do not take capsules that are broken or cracked.\u003c\/p\u003e\n\n\u003cp\u003eIf you vomit after taking palbociclib, do not take another dose. Continue your regular dosing schedule.\u003c\/p\u003e\n\n\u003cp\u003eYour doctor may decrease your dose or temporarily or permanently stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with palbociclib.\u003c\/p\u003e\n\n\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e\n\n\u003cp\u003eOther uses for this medicine\u003cbr\u003e\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e\n\n\u003cp\u003eWhat side effects can this medication cause?\u003cbr\u003e\nPalbociclib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003cbr\u003e\nnausea\u003cbr\u003e\ndiarrhea\u003cbr\u003e\nvomiting\u003cbr\u003e\ndecreased appetite\u003cbr\u003e\nchanges in taste\u003cbr\u003e\ntiredness\u003cbr\u003e\nnumbness or tingling in your arms, hands, legs, and feet\u003cbr\u003e\nsores on the lips, mouth, or throat\u003cbr\u003e\nunusual hair thinning or hair loss\u003cbr\u003e\ndry skin\u003cbr\u003e\nrash.\u003c\/p\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797945774123,"sku":"RL1420230901138","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655194988-1765ff1a7189095.png?v=1787022063"},{"product_id":"pholorla-100-lorlatinib","title":"OLADX 50 (Olaparib)","description":"\u003ch2\u003eAbout Olaparib\u003c\/h2\u003e\u003cp\u003eOlaparib is a poly (ADP ribose) polymerase (PARP) inhibitor, at least before monotherapy Germline BRCA gene mutations associated with harmful or suspected harmful after 3 chemotherapy (FDA also approved the gene Detection reagent) for patients with advanced ovarian cancer.\u003c\/p\u003e\u003cp\u003eOlaparib was approved by the FDA due to its objective response rate and response duration. Further of this indication\u003c\/p\u003e\u003cp\u003eApproval depends on the results of clinical benefit in confirmatory clinical trials.\u003c\/p\u003e\u003ch2\u003eDose and administration method\u003c\/h2\u003e\u003col\u003e\u003cli\u003eMethod of administration\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\n\u003cli\u003eThe recommended dose is 400 mg twice a day, orally, either before or after meals.\u003c\/li\u003e\n\u003cli\u003eContinue to use until the disease progresses or unacceptable toxicity occurs.\u003c\/li\u003e\n\u003cli\u003eIf adverse reactions occur, consider discontinuing the medication or reducing the dose.\u003c\/li\u003e\n\u003cli\u003eFor patients with mild renal impairment (creatinine clearance (CLcr)=31-50mL\/min), the dose is reduced 300mg\/time.\u003c\/li\u003e\n\u003c\/ul\u003e\u003col start=\"2\"\u003e\u003cli\u003eDosage specifications\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\u003cli\u003eCapsule, 50mg.\u003c\/li\u003e\u003c\/ul\u003e\u003col start=\"3\"\u003e\u003cli\u003eContraindications: None.\u003c\/li\u003e\u003c\/ol\u003e\u003ch2\u003eWarnings and Precautions\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eMyelodysplastic syndrome\/acute myelogenous leukemia (MDS\/AML): The patient is taking European MDS\/AML appeared after Lini, and a large number of reports were fatal. Baseline monitoring of whole blood cells every month after treatment Cell count. Once diagnosed with MDS\/AML, Orini was stopped immediately.\u003c\/li\u003e\n\u003cli\u003ePneumonia: The patient develops pneumonia after taking Olini. In some cases, it is fatal. Once the lungs appear The treatment was discontinued for inflammatory symptoms, and Olini was discontinued after diagnosis.\u003c\/li\u003e\n\u003cli\u003eFetal-embryotoxicity: Olini can be fatal to the fetus. Advise women with reproductive capacity to suffer Patients take effective contraceptive measures during treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAdverse reactions\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eCommon adverse reactions (≥20%) in clinical trials include anemia, nausea, fatigue (including weakness), Vomiting, diarrhea, dizziness, indigestion, headache, loss of appetite, nasopharyngitis\/pharyngitis\/URI, cough, close Joint pain\/muscle pain, back pain, dermatitis\/rash, abdominal pain\/discomfort.\u003c\/li\u003e\n\u003cli\u003eCommon laboratory abnormalities (≥25%) include: creatinine, increase in average red blood cell volume; blood Globin, lymphocytes, absolute neutrophils, thrombocytopenia.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eStorage method\u003c\/h2\u003e\u003cp\u003eStore between 20-25°C.\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797945872427,"sku":"RL3020240925","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-09-2018.jpg?v=1787022064"},{"product_id":"olieni-olaparib-50mg-2","title":"Olieni 50 (Olaparib)","description":" \r\n\u003cdiv class=\"woocommerce-product-details__short-description\"\u003e\r\n\r\n\u003cstrong\u003eIndications\u003c\/strong\u003e\r\n\r\nOlieni is a poly (ADP ribose) polymerase (PARP) inhibitor, at least before monotherapy Germline BRCA gene mutations associated with harmful or suspected harmful after 3 chemotherapy (FDA also approved the gene Detection reagent) for patients with advanced ovarian cancer.\r\n\r\nOlieni was approved by the FDA due to its objective response rate and response duration. Further of this indication\r\n\r\nApproval depends on the results of clinical benefit in confirmatory clinical trials.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cstrong\u003eDose and administration method\u003c\/strong\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eMethod of administration\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eThe recommended dose is 400 mg twice a day, orally, either before or after meals.\u003c\/li\u003e\r\n \t\u003cli\u003eContinue to use until the disease progresses or unacceptable toxicity occurs.\u003c\/li\u003e\r\n \t\u003cli\u003eIf adverse reactions occur, consider discontinuing the medication or reducing the dose.\u003c\/li\u003e\r\n \t\u003cli\u003eFor patients with mild renal impairment (creatinine clearance (CLcr)=31-50mL\/min), the dose is reduced 300mg\/time.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"2\"\u003e\r\n \t\u003cli\u003eDosage specifications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eCapsule, 50mg.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"3\"\u003e\r\n \t\u003cli\u003eContraindications: None.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cstrong\u003eWarnings and Precautions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMyelodysplastic syndrome\/acute myelogenous leukemia (MDS\/AML): The patient is taking European MDS\/AML appeared after Lini, and a large number of reports were fatal. Baseline monitoring of whole blood cells every month after treatment Cell count. Once diagnosed with MDS\/AML, Orini was stopped immediately.\u003c\/li\u003e\r\n \t\u003cli\u003ePneumonia: The patient develops pneumonia after taking Olini. In some cases, it is fatal. Once the lungs appear The treatment was discontinued for inflammatory symptoms, and Olini was discontinued after diagnosis.\u003c\/li\u003e\r\n \t\u003cli\u003eFetal-embryotoxicity: Olini can be fatal to the fetus. Advise women with reproductive capacity to suffer Patients take effective contraceptive measures during treatment.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAdverse reactions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eCommon adverse reactions (≥20%) in clinical trials include anemia, nausea, fatigue (including weakness), Vomiting, diarrhea, dizziness, indigestion, headache, loss of appetite, nasopharyngitis\/pharyngitis\/URI, cough, close Joint pain\/muscle pain, back pain, dermatitis\/rash, abdominal pain\/discomfort.\u003c\/li\u003e\r\n \t\u003cli\u003eCommon laboratory abnormalities (≥25%) include: creatinine, increase in average red blood cell volume; blood Globin, lymphocytes, absolute neutrophils, thrombocytopenia.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eStorage method\u003c\/strong\u003e\r\n\r\nStore between 20-25°C.\r\n\r\n\u003c\/div\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947478059,"sku":"RL1420230901255","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655264792-96bfa0933e18e60.jpg?v=1787022095"},{"product_id":"olieni-olaparib-100mg","title":"Olieni 100 (Olaparib)","description":" \r\n\u003ch3\u003e\u003cstrong\u003eIndications\u003c\/strong\u003e\u003c\/h3\u003e\r\nOlaparib is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eMedical uses\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib is indicated to treat breast cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, and prostate cancer.\r\n\r\nWhy is this medication prescribed?\r\nOlaparib tablets are used to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Olaparib tablets are also used to treat certain types of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other therapies. Olaparib tablets are also used to treat a certain type of prostate cancer that has spread to other parts of the body, no longer responds to medical or surgical treatments to lower testosterone levels, and has progressed after treatment with enzalutamide (Xtandi) or abiraterone (Yonsa, Zytiga). Olaparib tablets and capsules are also used to treat ovarian cancer that has not improved or has worsened after treatment with at least three other therapies. Olaparib tablets are also used to help maintain the response of a certain type of pancreatic cancer that has not spread or progressed after the first chemotherapy treatment. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eMedicine usage\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib comes as a tablet or a capsule to take by mouth twice daily with or without food. Try to space your doses about 12 hours apart. Take olaparib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take olaparib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\r\n\r\nSwallow the tablet or capsule whole; do not crush chew, divide, or dissolve them.\r\n\r\nOlaparib is available as a tablet and as a capsule. The tablets and capsules contain different amounts of olaparib and should not be substituted for one another. Talk to your doctor or pharmacist if you have any questions about the tablet and capsule preparations.\r\n\r\nYour doctor may decrease your dose of olaparib or tell you to stop taking olaparib for a period of time during your treatment. This will depend on how well the medication works for you and any side effects you may experience. Be sure to tell your doctor how you are feeling during your treatment with olaparib.\r\n\r\nYour doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with olaparib. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm085729.htm) to obtain the Medication Guide.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eOther uses for this medicine\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003eside effects\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\r\nnausea\r\nvomiting\r\ndiarrhea\r\nconstipation\r\nheartburn\r\nheadache\r\ndecreased appetite\r\nmuscle, joint, or back pain\r\nfatigue\r\nstomach pain or discomfort\r\ntaste changes\r\nmouth pain or sores\r\nanxiety\r\ndepression\r\ndry skin\r\nitching\r\nrash\r\ndifficulty falling asleep or staying asleep","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947543595,"sku":"RL1420230901169","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663225716-df2184f4b46de3d.png?v=1787022096"},{"product_id":"parcini-125-palbociclib","title":"Parcini 125 (Palbociclib)","description":"\u003cp\u003ePalbociclib is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4\/6 inhibitor to be approved as a cancer therapy.\u003c\/p\u003e\n\n\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003e\nPalbociclib is used in combination with anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor–positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in women who have experienced menopause (change of life; end of monthly menstrual periods) or in men. Palbociclib is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor–positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in people who have been treated with an antiestrogen medication such as tamoxifen (Nolvadex). Palbociclib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eHow should this medicine be used?\u003cbr\u003e\nPalbociclib comes as a capsule to take by mouth. It is usually taken with food once daily for the first 21 days of a 28-day cycle. Your doctor will decide how many times you should repeat this cycle. Take palbociclib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take palbociclib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\n\n\u003cp\u003eSwallow the capsules whole; do not open, chew, or crush them. Do not take capsules that are broken or cracked.\u003c\/p\u003e\n\n\u003cp\u003eIf you vomit after taking palbociclib, do not take another dose. Continue your regular dosing schedule.\u003c\/p\u003e\n\n\u003cp\u003eYour doctor may decrease your dose or temporarily or permanently stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with palbociclib.\u003c\/p\u003e\n\n\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e\n\n\u003cp\u003eOther uses for this medicine\u003cbr\u003e\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e\n\n\u003cp\u003eWhat side effects can this medication cause?\u003cbr\u003e\nPalbociclib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003cbr\u003e\nnausea\u003cbr\u003e\ndiarrhea\u003cbr\u003e\nvomiting\u003cbr\u003e\ndecreased appetite\u003cbr\u003e\nchanges in taste\u003cbr\u003e\ntiredness\u003cbr\u003e\nnumbness or tingling in your arms, hands, legs, and feet\u003cbr\u003e\nsores on the lips, mouth, or throat\u003cbr\u003e\nunusual hair thinning or hair loss\u003cbr\u003e\ndry skin\u003cbr\u003e\nrash.\u003c\/p\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948035115,"sku":"RL1420230901171","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655265698-2b0c2132e8ad5d8.png?v=1787022106"},{"product_id":"olieni-olaparib-150mg-2","title":"Olieni 150 (Olaparib)","description":"\u003ch3\u003e\u003cstrong\u003eIndications\u003c\/strong\u003e\u003c\/h3\u003e\r\nOlaparib is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eMedical uses\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib is indicated to treat breast cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, and prostate cancer.\r\n\r\nWhy is this medication prescribed?\r\nOlaparib tablets are used to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Olaparib tablets are also used to treat certain types of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other therapies. Olaparib tablets are also used to treat a certain type of prostate cancer that has spread to other parts of the body, no longer responds to medical or surgical treatments to lower testosterone levels, and has progressed after treatment with enzalutamide (Xtandi) or abiraterone (Yonsa, Zytiga). Olaparib tablets and capsules are also used to treat ovarian cancer that has not improved or has worsened after treatment with at least three other therapies. Olaparib tablets are also used to help maintain the response of a certain type of pancreatic cancer that has not spread or progressed after the first chemotherapy treatment. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eMedicine usage\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib comes as a tablet or a capsule to take by mouth twice daily with or without food. Try to space your doses about 12 hours apart. Take olaparib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take olaparib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\r\n\r\nSwallow the tablet or capsule whole; do not crush chew, divide, or dissolve them.\r\n\r\nOlaparib is available as a tablet and as a capsule. The tablets and capsules contain different amounts of olaparib and should not be substituted for one another. Talk to your doctor or pharmacist if you have any questions about the tablet and capsule preparations.\r\n\r\nYour doctor may decrease your dose of olaparib or tell you to stop taking olaparib for a period of time during your treatment. This will depend on how well the medication works for you and any side effects you may experience. Be sure to tell your doctor how you are feeling during your treatment with olaparib.\r\n\r\nYour doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with olaparib. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm085729.htm) to obtain the Medication Guide.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eOther uses for this medicine\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003eside effects\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\r\nnausea\r\nvomiting\r\ndiarrhea\r\nconstipation\r\nheartburn\r\nheadache\r\ndecreased appetite\r\nmuscle, joint, or back pain\r\nfatigue\r\nstomach pain or discomfort\r\ntaste changes\r\nmouth pain or sores\r\nanxiety\r\ndepression\r\ndry skin\r\nitching\r\nrash\r\ndifficulty falling asleep or staying asleep\r\npain urinating.","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948559403,"sku":"RL1420230901238","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1653881111-0cec2b187d0d386.jpg?v=1787022117"},{"product_id":"generic-abemaciclib-abedx-2","title":"BESIDX (Abemaciclib)","description":"\u003cp\u003eAbemaciclib is used in combination with an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer. Abemaciclib is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor-positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body after treatment with an antiestrogen medication such as tamoxifen. Abemaciclib is also used along with anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) as a first treatment of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body. Abemaciclib is also used alone to treat a certain type of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body in people who have already been treated with an antiestrogen medication and chemotherapy. Abemaciclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Early_Breast_Cancer\"\u003eEarly Breast Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, nodepositive, early breast cancer at high risk of recurrence\u003c\/p\u003e\u003cp\u003e150 mg PO BID PLUS tamoxifen or an aromatase inhibitor (see Prescribing Information)\u003c\/p\u003e\u003cp\u003eContinue for 2 years, or until disease recurrence or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Advanced_or_Metastatic_Breast_Cancer\"\u003eAdvanced or Metastatic Breast Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Monotherapy\"\u003eMonotherapy\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated as monotherapy for adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in metastatic setting\u003c\/li\u003e\n\u003cli\u003e200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_aromatase_inhibitor\"\u003eCombination therapy with aromatase inhibitor\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with an aromatase inhibitor as initial endocrine-based therapy for HR-positive, HER2-negative advanced or metastatic breast cancer\u003c\/li\u003e\n\u003cli\u003e150 mg PO BID PLUS an aromatase inhibitor (see Prescribing Information)\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_fulvestrant\"\u003eCombination therapy with fulvestrant\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated, in combination with fulvestrant, for adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy\u003c\/li\u003e\n\u003cli\u003e150 mg PO BID PLUS\u003c\/li\u003e\n\u003cli\u003eFulvestrant 500 mg IM on Days 1, 15, and 29, and then once monthly thereafter\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_effects\"\u003eDosage modifications for adverse effects\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Combined_with_fulvestrant_tamoxifen_or_aromatase_inhibitor\"\u003eCombined with fulvestrant, tamoxifen, or aromatase inhibitor\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 150 mg BID\u003c\/li\u003e\n\u003cli\u003eFirst dose reduction: 100 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eDiscontinue if unable to tolerate 50 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Monotherapy1\"\u003eMonotherapy\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 200 mg BID\u003c\/li\u003e\n\u003cli\u003eFirst dose reduction: 150 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 100 mg BID\u003c\/li\u003e\n\u003cli\u003eThird dose reduction: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eDiscontinue if unable to tolerate 50 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949607979,"sku":"RL1820240701","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-06-2439.jpg?v=1787022132"},{"product_id":"generic-tucatinib-tukadx","title":"TUKADX (Tucatinib)","description":"\u003cp\u003e\u003cstrong\u003eTucatinib \u003c\/strong\u003e is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. \u003c\/p\u003e\u003ch3\u003eAdvanced or Metastatic Breast Cancer\u003c\/h3\u003e\u003cp\u003eIndicated in combination with trastuzumab and capecitabine for treatment of advanced unresectable or metastatic human epidermal growth factor (HER2)-positive breast cancer (including brain metastases) in patients who have received ≥1 anti-HER2-based regimens in the metastatic setting\u003c\/p\u003e\u003cp\u003e300 mg PO BID in combination with trastuzumab and capecitabine\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eRefer to the full prescribing information for trastuzumab and capecitabine for additional information\u003c\/p\u003e\u003ch3\u003eColorectal Cancer\u003c\/h3\u003e\u003cp\u003eIndicated in combination with trastuzumab for RAS wild-type HER 2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy\u003c\/p\u003e\u003cp\u003e300 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eRefer to the full prescribing information for trastuzumab for additional inforation\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eRefer to the full prescribing information for trastuzumab and capecitabine for dosage modifications\u003c\/p\u003e\u003ch4\u003eDose reductions for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst reduction: 250 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eThird reduction: 150 PO BID\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 150 mg PO BID: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDiarrhea\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 without antidiarrheal treatment: Initiate or intensify appropriate medical therapy; hold until recovery to Grade ≤1, then resume at same dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 with antidiarrheal therapy: Initiate or intensify appropriate medical therapy; hold until recovery to Grade ≤1, then resume at same dose or at next lower dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatotoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 2 bilirubin (\u0026gt;1.5 to 3x ULN): Hold until recovery to Grade ≤1, then resume at same dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 ALT or AST (\u0026gt;5 to 20x ULN) OR Grade 3 bilirubin (\u0026gt;3 to 10x ULN): Hold until recovery to Grade ≤1, then resume at next lower dose\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003ePermanently discontinue\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eGrade 4 ALT\/AST (\u0026gt;20x ULN) OR Grade 4 bilirubin (\u0026gt;10x ULN)\u003c\/li\u003e\n\u003cli\u003eALT\/AST \u0026gt;3x ULN AND bilirubin \u0026gt;2x ULN\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Hold until recovery to Grade ≤1, then resume at next lower dose level\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCoadministration with strong CYP2C8 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration; if unavoidable, reduce tucatinib to 100 mg PO BID\u003c\/li\u003e\n\u003cli\u003eAfter discontinuing strong CYP2C8 inhibitor for 3 elimination half-lives, resume tucatinib dose taken before initiating inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Use in combination with trastuzumab and capecitabine is not recommended; capecitabine is contraindicated in patients with severe renal impairment\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Reduce to 200 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status of females of reproductive potential before initiating\u003c\/p\u003e\u003ch4\u003eSelect patients for unresectable or metastatic colorectal cancer\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eBased on presence of HER2 overexpression or gene amplification and RAS wild-type\u003c\/li\u003e\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797950328875,"sku":"RL2320240201950","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-09-1762.jpg?v=1787022151"},{"product_id":"loqtorzi-toripalimab","title":"Loqtorzi (Toripalimab)","description":"\u003ch2\u003eAbout Toripalimab\u003c\/h2\u003e\u003cp\u003eToripalimab-tpzi is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD⁠-⁠1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eToripalimab  sold under the brand name LOQTORZI\u003csup\u003e®\u003c\/sup\u003e in Europe.\u003c\/li\u003e\n\u003cli\u003eToripalimab  sold under the brand name ZYTORVI\u003csup\u003e®\u003c\/sup\u003e in India.\u003c\/li\u003e\n\u003cli\u003eToripalimab  sold under the brand name 拓益\u003csup\u003e®\u003c\/sup\u003e in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eApproved\u003c\/h2\u003e\u003ch3\u003eOn October 27, 2023\u003c\/h3\u003e\u003cp\u003eThe FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC).\u003c\/p\u003e\u003cp\u003eFDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.\u003c\/p\u003e\u003ch3\u003eSeptember 24, 2024\u003c\/h3\u003e\u003cp\u003eShanghai -- On September 24, 2024, Beijing time, Junshi Biosciences (1877.HK, 688180.SH) announced that the company's independently developed anti-PD-1 monoclonal antibody drug Toripalimab (European trade name: LOQTORZI®) has recently been approved by the European Commission (EC) for the treatment of two indications:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eToripalimab combined with cisplatin and gemcitabine is used for the first-line treatment of adult patients with recurrent, inoperable or radiotherapy-intolerant, or metastatic nasopharyngeal carcinoma (NPC);\u003c\/li\u003e\n\u003cli\u003eToripalimab combined with cisplatin and paclitaxel is used for the first-line treatment of adult patients with unresectable advanced\/recurrent or metastatic esophageal squamous cell carcinoma (ESCC).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Junshi Biosciences, China","offers":[{"title":"Default Title","offer_id":44797952229419,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-22100.jpg?v=1787022170"},{"product_id":"avzivi-bevacizumab","title":"Avzivi (Bevacizumab)","description":"\u003cp\u003eAvzivi® (Bevacizumab-tnjn)  sold under the brand name POBEVCY (普贝希) in China, is a humanized monoclonal antibody that targets VEGF. It specifically binds to VEGF and blocks the binding of VEGF to its receptor, thereby reducing neovascularization, inducing the degradation of existing blood vessels, and thereby inhibiting tumor growth. \u003c\/p\u003e\u003cp\u003eDec 7, 2023，The FDA has approved the fifth bevacizumab biosimilar, Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) for the treatment of several types of cancer. Avzivi\u003csup\u003e®\u003c\/sup\u003e (BAT1706) is Bio-Thera Solutions’ second FDA approved product in the United States. Avzivi\u003csup\u003e®\u003c\/sup\u003e is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States.\u003c\/p\u003e","brand":"Bio-Thera Solutions, China","offers":[{"title":"Default Title","offer_id":44797952360491,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-2233.png?v=1787022174"},{"product_id":"hanquyou-trastuzumab","title":"HANQUYOU (Trastuzumab)","description":"\u003cp\u003eHANQUYOU® (Trastuzumab)  sold under the brand name 汉曲优® in china, Since its launch, 汉曲优® has been successfully approved for marketing in more than 40 countries and regions including China, the United Kingdom, France, Germany, Switzerland, Australia, Finland, Spain, Argentina, Saudi Arabia, and Singapore.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAmerica（USA） trade name: HERCESSI™\u003c\/li\u003e\n\u003cli\u003eEuropean trade name: Zercepac®\u003c\/li\u003e\n\u003cli\u003eAustralian trade names: Tuzucip® and Trastucip®\u003c\/li\u003e\n\u003cli\u003eThaiLand trade name: TRAZHER®\u003c\/li\u003e\n\u003cli\u003ePhilippine trade name: Hertumab®\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eTrastuzumab is a targeted cancer drug. It is a treatment for cancers that have large amounts of a protein called human epidermal growth factor receptor 2 (HER2) . \u003c\/p\u003e","brand":"Shanghai Henlius Biotech, China","offers":[{"title":"Default Title","offer_id":44797952557099,"sku":"RL24202403","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-03-0795.png?v=1787022180"},{"product_id":"generic-olaparib-oladx-150","title":"OLADX 150 (Olaparib)","description":"\u003ch2\u003e\u003cspan id=\"About_Olaparib\"\u003eAbout Olaparib\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eOlaparib is a poly (ADP ribose) polymerase (PARP) inhibitor, at least before monotherapy Germline BRCA gene mutations associated with harmful or suspected harmful after 3 chemotherapy (FDA also approved the gene Detection reagent) for patients with advanced ovarian cancer.\u003c\/p\u003e\u003cp\u003eOlaparib was approved by the FDA due to its objective response rate and response duration. Further of this indication\u003c\/p\u003e\u003cp\u003eApproval depends on the results of clinical benefit in confirmatory clinical trials.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dose_and_administration_method\"\u003eDose and administration method\u003c\/span\u003e\u003c\/h2\u003e\u003col\u003e\u003cli\u003eMethod of administration\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\n\u003cli\u003eThe recommended dose is 400 mg twice a day, orally, either before or after meals.\u003c\/li\u003e\n\u003cli\u003eContinue to use until the disease progresses or unacceptable toxicity occurs.\u003c\/li\u003e\n\u003cli\u003eIf adverse reactions occur, consider discontinuing the medication or reducing the dose.\u003c\/li\u003e\n\u003cli\u003eFor patients with mild renal impairment (creatinine clearance (CLcr)=31-50mL\/min), the dose is reduced 300mg\/time.\u003c\/li\u003e\n\u003c\/ul\u003e\u003col start=\"2\"\u003e\u003cli\u003eDosage specifications\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\u003cli\u003eCapsule, 50mg.\u003c\/li\u003e\u003c\/ul\u003e\u003col start=\"3\"\u003e\u003cli\u003eContraindications: None.\u003c\/li\u003e\u003c\/ol\u003e\u003ch2\u003e\u003cspan id=\"Warnings_and_Precautions\"\u003eWarnings and Precautions\u003c\/span\u003e\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eMyelodysplastic syndrome\/acute myelogenous leukemia (MDS\/AML): The patient is taking European MDS\/AML appeared after Lini, and a large number of reports were fatal. Baseline monitoring of whole blood cells every month after treatment Cell count. Once diagnosed with MDS\/AML, Orini was stopped immediately.\u003c\/li\u003e\n\u003cli\u003ePneumonia: The patient develops pneumonia after taking Olini. In some cases, it is fatal. Once the lungs appear The treatment was discontinued for inflammatory symptoms, and Olini was discontinued after diagnosis.\u003c\/li\u003e\n\u003cli\u003eFetal-embryotoxicity: Olini can be fatal to the fetus. Advise women with reproductive capacity to suffer Patients take effective contraceptive measures during treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"Adverse_reactions\"\u003eAdverse reactions\u003c\/span\u003e\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eCommon adverse reactions (≥20%) in clinical trials include anemia, nausea, fatigue (including weakness), Vomiting, diarrhea, dizziness, indigestion, headache, loss of appetite, nasopharyngitis\/pharyngitis\/URI, cough, close Joint pain\/muscle pain, back pain, dermatitis\/rash, abdominal pain\/discomfort.\u003c\/li\u003e\n\u003cli\u003eCommon laboratory abnormalities (≥25%) include: creatinine, increase in average red blood cell volume; blood Globin, lymphocytes, absolute neutrophils, thrombocytopenia.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"Storage_method\"\u003eStorage method\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eStore between 20-25°C.\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953277995,"sku":"RL3020241020345","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-153-jpg.webp?v=1787022196"},{"product_id":"irene-pyrotinib","title":"Irene (Pyrotinib)","description":"\u003ch2\u003eAbout Pyrotinib\u003c\/h2\u003e\u003cp\u003eIrene (Pyrotinib) sold under the brand name 艾瑞妮 in china, Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. \u003c\/p\u003e\u003ch2 id=\"Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer\" class=\"title !m-0 break-words text-dark-grey\" data-sb-field-path=\".title\"\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eBased on this phase II study, pyrotinib in combination with capecitabine received its first conditional approval in China for the treatment of HER2-positive, advanced or metastatic breast cancer previously exposed to anthracycline or taxane chemotherapy. \u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dosage_and_administration\"\u003eDosage\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eDepending on the indication, pyrotinib is taken orally at a standard dose of \u003cb\u003e400 mg\/day\u003c\/b\u003e. Dosage adjustments, combination, or non-combination of any antineoplastic agents are considered according to the physician's decision-making, the patient's previous treatment regimen, and the patient's own circumstances and wishes.\u003c\/p\u003e","brand":"Jiangsu Hengrui Medicine, China","offers":[{"title":"Default Title","offer_id":44797953572907,"sku":"RL2320241030400","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2788.png?v=1787022206"},{"product_id":"luciribo-ribociclib","title":"LuciRibo (Ribociclib)","description":"\u003ch2\u003eAbout Ribociclib\u003c\/h2\u003e\u003cp\u003eRibociclib is a targets proteins called cyclin dependant kinase 4 and cyclin dependant 6 (CDK 4 and CDK 6) on breast cancer cells. CDK 4 and CDK 6 are proteins that stimulate cancer cells to divide and grow. Ribociclib works by blocking these proteins.\u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003ch4\u003eEarly breast cancer\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with an aromatase inhibitor for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence\u003c\/li\u003e\n\u003cli\u003e400 mg PO daily for 21 consecutive days followed by 7 days off treatment\u003c\/li\u003e\n\u003cli\u003eRepeat in 28-day cycles for 3 years or until disease recurrence or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eRefer to prescribing information for the recommended dose of the aromatase inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eAdvanced or metastatic breast cancer\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for HR-positive, HER2-negative advanced or metastatic breast cancer\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eIn combination with an aromatase inhibitor as initial endocrine-based therapy\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e600 mg PO daily for 21 consecutive days followed by 7 days off treatment\u003c\/li\u003e\n\u003cli\u003eRepeat in 28-day cycles until disease recurrence or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eRefer to prescribing information for the recommended dose of the aromatase inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eIn combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e600 mg PO daily for 21 consecutive days followed by 7 days off treatment; repeat in 28-day cycles until disease recurrence or unacceptable toxicity, \u003cstrong\u003ePLUS\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFulvestrant 500 mg IM on Days 1,15, and 29, followed by 500 mg IM monthly thereafter\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eReview the prescribing information for the coadministered aromatase inhibitor or fulvestrant for dosage modifications\u003c\/p\u003e\u003ch4\u003eRecommended dose modifications for adverse effects\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eEarly breast cancer\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 400 mg\/day\u003c\/li\u003e\n\u003cli\u003eDose reduction: 200 mg\/day; discontinue if further dose adjustment is required\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eAdvanced or metastatic breast cancer\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 600 mg\/day\u003c\/li\u003e\n\u003cli\u003eFirst dose reduction: 400 mg\/day\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg\/day; discontinue if further dose adjustment is required\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954883627,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0937.jpg?v=1787022230"},{"product_id":"lucialpe-alpelisib","title":"LuciAlpe (Alpelisib)","description":"\u003ch2\u003eAbout Alpelisib\u003c\/h2\u003e\u003cp\u003eAlpelisib is a medication used to treat certain types of breast cancer.\u003csup id=\"cite_ref-FDA2019_8-0\" class=\"reference\"\u003e\u003c\/sup\u003e It is used together with fulvestrant.\u003csup id=\"cite_ref-FDA2019_8-1\" class=\"reference\"\u003e\u003c\/sup\u003e\u003csup id=\"cite_ref-FDA2019_8-4\" class=\"reference\"\u003e\u003c\/sup\u003e It is an alpha-specific PI3K inhibitor.\u003csup id=\"cite_ref-FDA2019_8-5\" class=\"reference\"\u003e\u003c\/sup\u003e \u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003cp\u003eKinase inhibitor indicated in combination with fulvestrant for treatment of men and pre-, peri-, or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen\u003c\/p\u003e\u003cp\u003eAlpelisib 300 mg PO qDay AND\u003c\/p\u003e\u003cp\u003eFulvestrant 500 mg IM on Days 1, 15, and 29, and once monthly thereafter\u003c\/p\u003e\u003cp\u003eContinue treatment until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003cp\u003eRefer to the full prescribing information for fulvestrant\u003c\/p\u003e\u003ch3\u003ePIK3CA-Related Overgrowth Spectrum\u003c\/h3\u003e\u003cp\u003eVijoice onlyIndicated for severe manifestations of PIK3CA-related overgrowth spectrum (PROS) in patients who require systemic therapy\u003c\/p\u003e\u003cp\u003e250 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955407915,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0974.jpg?v=1787022231"},{"product_id":"lucielace-elacestrant","title":"LuciElace (Elacestrant)","description":"\u003ch2\u003eAbout Elacestrant\u003c\/h2\u003e\u003cp\u003eAbout Elacestrant  is a selective estrogen receptor degrader (SERD) used in the treatment of breast cancer. Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors, which are the biological targets of endogenous estrogens like estradiol. \u003c\/p\u003e\u003cp\u003eElacestrant is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one other line of endocrine therapy.\u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for men or postmenopausal women with estrogen receptor positive (ER+), HER\u003csub\u003e2\u003c\/sub\u003e-negative, ESR\u003csub\u003e1\u003c\/sub\u003e-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy\u003c\/p\u003e\u003cp\u003e345 mg PO qDay with food until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose reduction recommendations for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 258 mg qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 172 mg qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if dose reduction \u0026lt;172 mg\/day required\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eModifications for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 1: Continue at current dose level\u003c\/li\u003e\n\u003cli\u003eGrade 2: Consider dose interruption until recovery to Grade ≤1 or baseline, then resume at same dose\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt dose until recovery to Grade ≤1 or baseline, then resume at next lower dose\u003c\/li\u003e\n\u003cli\u003eIf Grade 3 toxicity recurs, interrupt until recovery to Grade ≤1 or baseline, then resume elacestrant reduced by another dose level\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt dose until recovery to Grade ≤1 or baseline, then resume at next lower dose\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if Grade 4 or intolerable adverse reaction recurs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment recommended\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh B): Reduce dose to 258 mg qDay\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Avoid use; not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955538987,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1017.jpg?v=1787022234"},{"product_id":"lucicapiva-capivasertib","title":"LuciCapiva (Capivasertib)","description":"\u003ch2\u003eAbout Capivasertib\u003c\/h2\u003e\u003cp\u003eCapivasertib is an orally bioavailable, small-molecule inhibitor of all three AKT isoforms. Capivasertib used in combination with fulvestrant , is indicated for adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA\/AKT1\/PTEN-alterations,  following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within twelve months of completing adjuvant therapy.\u003csup id=\"cite_ref-Truqap_FDA_label_4-3\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003cp\u003eIndicated in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with ≥1 PIK3CA\/AKT1\/PTEN-alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting; or recurrence during, or within 12 months after completing, adjuvant therapy\u003c\/p\u003e\u003ch4\u003eCapivasertib weekly dose schedule\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e400 mg PO BID (~12 hr apart) x 4 consecutive days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eRepeat weekly schedule until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eFulvestrant regimen during clinical trial\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e28-day cycles\u003c\/li\u003e\n\u003cli\u003eCycle 1: 500 mg IM on Days 1 and 15\u003c\/li\u003e\n\u003cli\u003eSubsequent cycles: 500 mg IM on Day 1\u003c\/li\u003e\n\u003cli\u003ePremenopausal and perimenopausal women: Administer a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards\u003c\/li\u003e\n\u003cli\u003eMen: Consider administering a LHRH agonist according to current clinical practice standards\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose reductions for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 320 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHyperglycemia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eNote that recommendations are based on fasting glucose (FG) rather than random glucose\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFG \u0026gt;ULN-160 mg\/dL (8.9 mmol\/L) or hemoglobin A1C (HbA1C) \u0026gt;7%\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eConsider initiation or intensification of oral antidiabetic treatment\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFG 161-250 mg\/dL (9-13.9 mmol\/L)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until FG decrease to ≤160 mg\/dL (≤8.9 mmol\/L)\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days, resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days, resume at 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFG 251-500 mg\/dL (14-27.8 mmol\/L)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until FG decrease to ≤160 mg\/dL (≤8.9 mmol\/L)\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days, resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFG \u0026gt;500 mg\/dL (\u0026gt;27.8 mmol\/L) or life-threatening sequelae of hyperglycemia at any FG level\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eLife-threatening sequelae of hyperglycemia or if FG persists at ≥500 mg\/dL after 24 hr: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eIf FG ≤500 mg\/dL (or ≤27.8 mmol\/L) within 24 hr, follow above guidance for relevant grade\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDiarrhea\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose or 1 lower dose as clinically indicated\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eFor recurrence: Reduce by 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose or 1 lower dose as clinically indicated\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCutaneous reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1 then resume at same dose\u003c\/li\u003e\n\u003cli\u003ePersistent or recurrent: Reduce by 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eFor recurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResume at same dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong and moderate CYP3A inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eStrong inhibitor: Avoid coadministration; if unavoidable, reduce dose to 320 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eModerate inhibitor: Reduce dose to 320 mg PO BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eAfter discontinuing strong or moderate CYP3A inhibitor, resume capivasertib dosage (after 3-5 half-lives of CYP3A inhibitor) that was taken before initiating strong or moderate CYP3A inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl 15-29 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (bilirubin ULN \u003cb\u003eor\u003c\/b\u003e bilirubin \u0026gt;1-1.5x ULN and any AST): No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eModerate (bilirubin \u0026gt;1.5-3x ULN and any AST): Monitor for adverse reactions due to potential increased capivasertib exposure\u003c\/li\u003e\n\u003cli\u003eSevere (bilirubin \u0026gt;3x ULN and any AST): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955571755,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1022.jpg?v=1787022236"},{"product_id":"generic-eribulin-mesylate-injection","title":"Eribulin mesylate Injection","description":"\u003ch2\u003eAbout Eribulin mesylate Injection\u003c\/h2\u003e\u003cp\u003eEribulin is a chemotherapy drug.  It's a treatment for breast cancer and liposarcoma that has: spread to surrounding tissue (locally advanced cancer) spread to other areas of the body (metastatic or advanced cancer)\u003c\/p\u003e\u003cul\u003e\u003cli\u003eGeneric (Eribulin mesylate) sold as brand name 博立宁® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eBreast Cancer, Metastatic\u003c\/h3\u003e\u003cp\u003eIndicated for metastatic breast cancer in patients who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease; prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting\u003c\/p\u003e\u003cp\u003e1.4 mg\/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle \u003ca class=\"calc_link\" data-calc=\"bsa-dosing\" data-cond=\"\" data-sec=\"Adult Dosing \u0026amp; Uses\" data-text=\"1.4 mg\/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle\"\u003e \u003c\/a\u003e\u003c\/p\u003e\u003ch3\u003eLiposarcoma\u003c\/h3\u003e\u003cp\u003eIndicated for unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen\u003c\/p\u003e\u003cp\u003e1.4 mg\/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle \u003ca class=\"calc_link\" data-calc=\"bsa-dosing\" data-cond=\"\" data-sec=\"Adult Dosing \u0026amp; Uses\" data-text=\"1.4 mg\/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle\"\u003e \u003c\/a\u003e\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eAssess for peripheral neuropathy and obtain CBC counts prior to each dose\u003c\/p\u003e\u003ch4\u003eRecommended dose delays\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eDo not administer on Day 1 or Day 8 for any of the following\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eANC \u0026lt;1,000\/mm³\u003c\/li\u003e\n\u003cli\u003ePlatelets \u0026lt;75,000\/mm³\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 nonhematological toxicities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eThe Day 8 dose may be delayed for a maximum of 1 week:\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eIf toxicities do not resolve or improve to ≤Grade 2 severity by Day 15, omit the dose\u003c\/li\u003e\n\u003cli\u003eIf toxicities resolve or improved to ≤Grade 2 severity by Day 15, administer at a reduced dose and initiate the next cycle no sooner than 2 weeks later\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRecommended dose reductions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIf a dose has been delayed for toxicity and then recovered to ≤Grade 2 severity, resume at reduced doses (see below)\u003c\/li\u003e\n\u003cli\u003eDo not re-escalate once dose has been reduced\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003ePermanently reduce the 1.4 mg\/m² dose to 1.1 mg\/m² for any of the following:\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eANC \u0026lt;500\/mm³ for \u0026gt;7 days\u003c\/li\u003e\n\u003cli\u003eANC \u0026lt;1,000\/mm³ with fever or infection\u003c\/li\u003e\n\u003cli\u003ePlatelets \u0026lt;25,000\/mm³\u003c\/li\u003e\n\u003cli\u003ePlatelets \u0026lt;50,000\/mm³ requiring transfusion\u003c\/li\u003e\n\u003cli\u003eNonhematologic Grade 3 or 4 toxicities\u003c\/li\u003e\n\u003cli\u003eOmission or delay of Day 8 dose in previous cycle for toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003ePermanently reduce dose to 0.7 mg\/m² for any of the following:\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eOccurrence of any event requiring permanent dose reduction while receiving 1.1 mg\/m²\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eDiscontinue\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eOccurrence of any event requiring permanent dose reduction while receiving 0.7 mg\/m²\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eModerate-to-severe (CrCl 15-49 mL\/min): 1.1 mg\/m² IV\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): 1.1 mg\/m² IV\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh B): 0.7 mg\/m² IV\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BrightGene Bio-Medical Technology Co Ltd","offers":[{"title":"Default Title","offer_id":44797955833899,"sku":"RL3120241211s130","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1111.png?v=1787022242"},{"product_id":"entinostat","title":"Entinostat","description":"\u003cp\u003eEntinostat is a synthetic drug that inhibits histone deacetylase (HDAC) enzymes.\u003c\/p\u003e\u003cul\u003e\u003cli\u003eEntinostat sold as brand name 景助达®   in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eOn April 30, 2024, Entinostat was approved in China for use in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer that has recurred or progressed after endocrine therapy.\u003c\/p\u003e","brand":"EOC Pharma, China","offers":[{"title":"Default Title","offer_id":44797957242923,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-1788.jpg?v=1787022278"},{"product_id":"jiataile-sacituzumab-tirumotecan","title":"Jiataile (Sacituzumab Tirumotecan)","description":"\u003ch2\u003eAbout Sacituzumab tirumotecan\u003c\/h2\u003e\r\nSacituzumab tirumotecan, also known as sac-TMT, SKB264, or MK-2870, is an antibody-drug conjugate (ADC) being studied for various cancers, particularly non-small cell lung cancer (NSCLC) and breast cancer. It works by targeting and delivering a cytotoxic payload to cancer cells expressing the TROP2 protein.\r\n\r\nTROP2, a tumor-associated antigen expressed on many epithelial-derived tumors.The ADC binds to TROP2 on cancer cells, then releases a cytotoxic payload (an undisclosed topoisomerase I inhibitor) that inhibits tumor cell proliferation and causes cell death. Utilizes a unique Kthiol linker to attach the payload to the antibody, ensuring efficient delivery and release.\r\n\u003ch3\u003eApplications and Studies:\u003c\/h3\u003e\r\n\u003cstrong\u003eTriple-Negative Breast Cancer (TNBC)\u003c\/strong\u003e: Studies have shown a significant survival benefit in pretreated patients with advanced TNBC compared to chemotherapy.\r\n\r\n\u003ca href=\"https:\/\/www.onclive.com\/view\/sacituzumab-tirumotecan-earns-approval-in-china-in-pretreated-advanced-tnbc\"\u003e《Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC》\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eNon-Small Cell Lung Cancer (NSCLC)\u003c\/strong\u003e: Investigated in patients with advanced, previously treated NSCLC, including those with EGFR mutations.\r\n\r\n\u003ca href=\"https:\/\/www.onclive.com\/view\/china-s-nmpa-approves-sacituzumab-tirumotecan-for-pretreated-egfr-advanced-nsclc\"\u003e《China’s NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC》\u003c\/a\u003e\r\n\r\nOther Cancers:Clinical trials are underway exploring the use of sacituzumab tirumotecan in other cancers, such as gastric cancer and endometrial cancer.","brand":"KELUN-BIOTECH, China","offers":[{"title":"Default Title","offer_id":44797957931051,"sku":"RL3520250508","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-05-0735.png?v=1787022293"},{"product_id":"capivadx-160-capivasertib","title":"CAPIVADX 160 (Capivasertib)","description":"\u003ch2\u003e\u003cspan id=\"About_Capivasertib\"\u003eAbout Capivasertib\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eCapivasertib is an orally bioavailable, small-molecule inhibitor of all three AKT isoforms. Capivasertib used in combination with fulvestrant , is indicated for adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA\/AKT1\/PTEN-alterations,  following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within twelve months of completing adjuvant therapy.\u003csup id=\"cite_ref-Truqap_FDA_label_4-3\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Breast_Cancer\"\u003eBreast Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with ≥1 PIK3CA\/AKT1\/PTEN-alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting; or recurrence during, or within 12 months after completing, adjuvant therapy\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Capivasertib_weekly_dose_schedule\"\u003eCapivasertib weekly dose schedule\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e400 mg PO BID (~12 hr apart) x 4 consecutive days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eRepeat weekly schedule until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Fulvestrant_regimen_during_clinical_trial\"\u003eFulvestrant regimen during clinical trial\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e28-day cycles\u003c\/li\u003e\n\u003cli\u003eCycle 1: 500 mg IM on Days 1 and 15\u003c\/li\u003e\n\u003cli\u003eSubsequent cycles: 500 mg IM on Day 1\u003c\/li\u003e\n\u003cli\u003ePremenopausal and perimenopausal women: Administer a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards\u003c\/li\u003e\n\u003cli\u003eMen: Consider administering a LHRH agonist according to current clinical practice standards\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dose_reductions_for_adverse_reactions\"\u003eDose reductions for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 320 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hyperglycemia\"\u003eHyperglycemia\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eNote that recommendations are based on fasting glucose (FG) rather than random glucose\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"FG_ULN-160_mgdL_89_mmolL_or_hemoglobin_A1C_HbA1C_7\"\u003eFG \u0026gt;ULN-160 mg\/dL (8.9 mmol\/L) or hemoglobin A1C (HbA1C) \u0026gt;7%\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eConsider initiation or intensification of oral antidiabetic treatment\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"FG_161-250_mgdL_9-139_mmolL\"\u003eFG 161-250 mg\/dL (9-13.9 mmol\/L)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until FG decrease to ≤160 mg\/dL (≤8.9 mmol\/L)\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days, resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days, resume at 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"FG_251-500_mgdL_14-278_mmolL\"\u003eFG 251-500 mg\/dL (14-27.8 mmol\/L)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until FG decrease to ≤160 mg\/dL (≤8.9 mmol\/L)\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days, resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"FG_500_mgdL_278_mmolL_or_life-threatening_sequelae_of_hyperglycemia_at_any_FG_level\"\u003eFG \u0026gt;500 mg\/dL (\u0026gt;27.8 mmol\/L) or life-threatening sequelae of hyperglycemia at any FG level\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eLife-threatening sequelae of hyperglycemia or if FG persists at ≥500 mg\/dL after 24 hr: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eIf FG ≤500 mg\/dL (or ≤27.8 mmol\/L) within 24 hr, follow above guidance for relevant grade\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Diarrhea\"\u003eDiarrhea\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_2\"\u003eGrade 2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose or 1 lower dose as clinically indicated\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eFor recurrence: Reduce by 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_3\"\u003eGrade 3\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose or 1 lower dose as clinically indicated\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_4\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Cutaneous_reactions\"\u003eCutaneous reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_21\"\u003eGrade 2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1 then resume at same dose\u003c\/li\u003e\n\u003cli\u003ePersistent or recurrent: Reduce by 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_31\"\u003eGrade 3\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eFor recurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_41\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_22\"\u003eGrade 2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResume at same dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_32\"\u003eGrade 3\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_42\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_and_moderate_CYP3A_inhibitors\"\u003eStrong and moderate CYP3A inhibitors\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eStrong inhibitor: Avoid coadministration; if unavoidable, reduce dose to 320 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eModerate inhibitor: Reduce dose to 320 mg PO BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eAfter discontinuing strong or moderate CYP3A inhibitor, resume capivasertib dosage (after 3-5 half-lives of CYP3A inhibitor) that was taken before initiating strong or moderate CYP3A inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl 15-29 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (bilirubin ULN \u003cb\u003eor\u003c\/b\u003e bilirubin \u0026gt;1-1.5x ULN and any AST): No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eModerate (bilirubin \u0026gt;1.5-3x ULN and any AST): Monitor for adverse reactions due to potential increased capivasertib exposure\u003c\/li\u003e\n\u003cli\u003eSevere (bilirubin \u0026gt;3x ULN and any AST): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797958160427,"sku":"RL362025060604","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-06-0634.jpg?v=1787022297"},{"product_id":"capivadx-200-capivasertib","title":"CAPIVADX 200 (Capivasertib)","description":"\u003ch2\u003e\u003cspan id=\"About_Capivasertib\"\u003eAbout Capivasertib\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eCapivasertib is an orally bioavailable, small-molecule inhibitor of all three AKT isoforms. Capivasertib used in combination with fulvestrant , is indicated for adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA\/AKT1\/PTEN-alterations,  following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within twelve months of completing adjuvant therapy.\u003csup id=\"cite_ref-Truqap_FDA_label_4-3\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Breast_Cancer\"\u003eBreast Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with ≥1 PIK3CA\/AKT1\/PTEN-alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting; or recurrence during, or within 12 months after completing, adjuvant therapy\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Capivasertib_weekly_dose_schedule\"\u003eCapivasertib weekly dose schedule\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e400 mg PO BID (~12 hr apart) x 4 consecutive days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eRepeat weekly schedule until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Fulvestrant_regimen_during_clinical_trial\"\u003eFulvestrant regimen during clinical trial\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e28-day cycles\u003c\/li\u003e\n\u003cli\u003eCycle 1: 500 mg IM on Days 1 and 15\u003c\/li\u003e\n\u003cli\u003eSubsequent cycles: 500 mg IM on Day 1\u003c\/li\u003e\n\u003cli\u003ePremenopausal and perimenopausal women: Administer a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards\u003c\/li\u003e\n\u003cli\u003eMen: Consider administering a LHRH agonist according to current clinical practice standards\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dose_reductions_for_adverse_reactions\"\u003eDose reductions for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 320 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hyperglycemia\"\u003eHyperglycemia\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eNote that recommendations are based on fasting glucose (FG) rather than random glucose\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"FG_ULN-160_mgdL_89_mmolL_or_hemoglobin_A1C_HbA1C_7\"\u003eFG \u0026gt;ULN-160 mg\/dL (8.9 mmol\/L) or hemoglobin A1C (HbA1C) \u0026gt;7%\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eConsider initiation or intensification of oral antidiabetic treatment\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"FG_161-250_mgdL_9-139_mmolL\"\u003eFG 161-250 mg\/dL (9-13.9 mmol\/L)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until FG decrease to ≤160 mg\/dL (≤8.9 mmol\/L)\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days, resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days, resume at 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"FG_251-500_mgdL_14-278_mmolL\"\u003eFG 251-500 mg\/dL (14-27.8 mmol\/L)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until FG decrease to ≤160 mg\/dL (≤8.9 mmol\/L)\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days, resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"FG_500_mgdL_278_mmolL_or_life-threatening_sequelae_of_hyperglycemia_at_any_FG_level\"\u003eFG \u0026gt;500 mg\/dL (\u0026gt;27.8 mmol\/L) or life-threatening sequelae of hyperglycemia at any FG level\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eLife-threatening sequelae of hyperglycemia or if FG persists at ≥500 mg\/dL after 24 hr: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eIf FG ≤500 mg\/dL (or ≤27.8 mmol\/L) within 24 hr, follow above guidance for relevant grade\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Diarrhea\"\u003eDiarrhea\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_2\"\u003eGrade 2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose or 1 lower dose as clinically indicated\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eFor recurrence: Reduce by 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_3\"\u003eGrade 3\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose or 1 lower dose as clinically indicated\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_4\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Cutaneous_reactions\"\u003eCutaneous reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_21\"\u003eGrade 2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1 then resume at same dose\u003c\/li\u003e\n\u003cli\u003ePersistent or recurrent: Reduce by 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_31\"\u003eGrade 3\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eFor recurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_41\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_22\"\u003eGrade 2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResume at same dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_32\"\u003eGrade 3\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_42\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_and_moderate_CYP3A_inhibitors\"\u003eStrong and moderate CYP3A inhibitors\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eStrong inhibitor: Avoid coadministration; if unavoidable, reduce dose to 320 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eModerate inhibitor: Reduce dose to 320 mg PO BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eAfter discontinuing strong or moderate CYP3A inhibitor, resume capivasertib dosage (after 3-5 half-lives of CYP3A inhibitor) that was taken before initiating strong or moderate CYP3A inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl 15-29 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (bilirubin ULN \u003cb\u003eor\u003c\/b\u003e bilirubin \u0026gt;1-1.5x ULN and any AST): No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eModerate (bilirubin \u0026gt;1.5-3x ULN and any AST): Monitor for adverse reactions due to potential increased capivasertib exposure\u003c\/li\u003e\n\u003cli\u003eSevere (bilirubin \u0026gt;3x ULN and any AST): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797958193195,"sku":"RL362025060605","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-06-0612.jpg?v=1787022299"},{"product_id":"olanib-olaparib-inn-50-mg","title":"Olanib (Olaparib INN 50 mg )","description":"\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eOlanib 50 mg (Olaparib INN)\u003c\/strong\u003e is an oral anticancer medicine containing \u003cstrong\u003e50 mg of olaparib per hard capsule\u003c\/strong\u003e. It belongs to the \u003cstrong\u003ePARP inhibitor\u003c\/strong\u003e class and works by blocking PARP enzymes involved in DNA repair, making it particularly effective against certain cancers with \u003cstrong\u003eBRCA or other DNA-repair deficiencies\u003c\/strong\u003e. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eIt is used, depending on the cancer type and genetic status, in conditions such as \u003cstrong\u003eovarian, breast, pancreatic, and prostate cancers\u003c\/strong\u003e. Treatment should be prescribed and monitored by an oncology specialist. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e The 50-mg capsule is a specific formulation; olaparib tablet and capsule formulations are \u003cstrong\u003enot necessarily interchangeable milligram-for-milligram\u003c\/strong\u003e.\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44889605046315,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/OlanibINN50mg.jpg?v=1787208626"},{"product_id":"palboxen-palbociclib-inn-125-mg","title":"Palboxen (Palbociclib INN 125 mg)","description":"\u003cp\u003e\u003cstrong\u003ePalboxen (Palbociclib INN 125 mg)\u003c\/strong\u003e\u003cspan\u003e is an \u003c\/span\u003e\u003cstrong\u003eoncology medicine manufactured by Everest Pharmaceuticals Ltd., Bangladesh\u003c\/strong\u003e\u003cspan\u003e. It contains \u003c\/span\u003e\u003cstrong\u003ePalbociclib 125 mg\u003c\/strong\u003e\u003cspan\u003e, an oral targeted anticancer medicine that belongs to the \u003c\/span\u003e\u003cstrong\u003eCDK4\/6 inhibitor\u003c\/strong\u003e\u003cspan\u003e class. Palbociclib works by inhibiting cyclin-dependent kinases 4 and 6, helping slow the growth and division of cancer cells. It is used in the treatment of certain \u003c\/span\u003e\u003cstrong\u003ehormone receptor-positive, HER2-negative breast cancers\u003c\/strong\u003e\u003cspan\u003e, according to the approved indication and medical supervision. Everest officially lists \u003c\/span\u003e\u003cstrong\u003ePalboxen\u003c\/strong\u003e\u003cspan\u003e in its \u003c\/span\u003e\u003cstrong\u003eOncology\u003c\/strong\u003e\u003cspan\u003e product portfolio.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44890372014123,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Palboxen.jpg?v=1787233319"},{"product_id":"palbokin-125-palbociclib","title":"Palbokin 125 (Palbociclib)","description":"\u003cp\u003e\u003cstrong\u003ePalbokin 125 (Palbociclib)\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anti-cancer medicine containing \u003c\/span\u003e\u003cstrong\u003epalbociclib\u003c\/strong\u003e\u003cspan\u003e, a cyclin-dependent kinase (CDK) 4\/6 inhibitor that helps slow the growth and division of cancer cells. It is primarily used in combination with hormonal therapy for the treatment of \u003c\/span\u003e\u003cstrong\u003ehormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer\u003c\/strong\u003e\u003cspan\u003e. Palbokin 125 contains \u003c\/span\u003e\u003cstrong\u003e125 mg of palbociclib\u003c\/strong\u003e\u003cspan\u003e and is supplied in a \u003c\/span\u003e\u003cstrong\u003e21-capsule pack\u003c\/strong\u003e\u003cspan\u003e. \u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44896140034091,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/palbokin-125-160.jpg?v=1787298215"},{"product_id":"tukanic-150-tucatinib","title":"Tukanic 150 (Tucatinib)","description":"\u003cp\u003e\u003cstrong\u003eTukanic 150 (Tucatinib)\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anti-cancer medicine containing \u003c\/span\u003e\u003cstrong\u003etucatinib\u003c\/strong\u003e\u003cspan\u003e, a selective HER2 tyrosine kinase inhibitor that blocks HER2 signaling involved in the growth and spread of cancer cells. It is used in combination with other anticancer medicines for the treatment of \u003c\/span\u003e\u003cstrong\u003eHER2-positive breast cancer\u003c\/strong\u003e\u003cspan\u003e, including unresectable locally advanced or metastatic disease and certain patients with \u003c\/span\u003e\u003cstrong\u003ebrain metastases\u003c\/strong\u003e\u003cspan\u003e. Tukanic 150 contains \u003c\/span\u003e\u003cstrong\u003e150 mg of tucatinib\u003c\/strong\u003e\u003cspan\u003e and is supplied as tablets.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44896620380203,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/tukanic-150-168.jpg?v=1787305985"},{"product_id":"tukanic-150-tucatinib-inn","title":"TUKANIC 150 (TUCATINIB INN)","description":"\u003cp\u003e\u003cstrong\u003eTUKANIC (Tucatinib INN)\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anti-cancer medicine containing \u003c\/span\u003e\u003cstrong\u003etucatinib\u003c\/strong\u003e\u003cspan\u003e, a selective HER2 tyrosine kinase inhibitor that blocks HER2 signaling involved in cancer cell growth and spread. It is used in combination with other anticancer medicines for the treatment of \u003c\/span\u003e\u003cstrong\u003eHER2-positive breast cancer\u003c\/strong\u003e\u003cspan\u003e, including advanced or metastatic disease. TUKANIC is available in a \u003c\/span\u003e\u003cstrong\u003e30-tablet pack\u003c\/strong\u003e\u003cspan\u003e and is classified as an \u003c\/span\u003e\u003cstrong\u003eanti-cancer\u003c\/strong\u003e\u003cspan\u003e medicine. \u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44896732348459,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/tukanic-150.png?v=1787308531"},{"product_id":"palbokin-palbociclib","title":"PALBOKIN (PALBOCICLIB)","description":"\u003cp\u003e\u003cstrong\u003ePALBOKIN (PALBOCICLIB)\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anti-cancer medicine containing \u003c\/span\u003e\u003cstrong\u003epalbociclib\u003c\/strong\u003e\u003cspan\u003e, a CDK4\/6 inhibitor that helps slow the growth and division of cancer cells. It is primarily used in combination with hormonal therapy for \u003c\/span\u003e\u003cstrong\u003ehormone receptor-positive, HER2-negative advanced or metastatic breast cancer\u003c\/strong\u003e\u003cspan\u003e. PALBOKIN is listed as an \u003c\/span\u003e\u003cstrong\u003eanti-cancer\u003c\/strong\u003e\u003cspan\u003e medicine with a \u003c\/span\u003e\u003cstrong\u003e21-tablet\/capsule pack\u003c\/strong\u003e\u003cspan\u003e, depending on the specific presentation.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44897023655979,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/palbokin-334.png?v=1787314688"},{"product_id":"tucaxen-150mg-tucatinib","title":"Tucaxen 150mg (Tucatinib)","description":"\u003cp\u003e\u003cstrong\u003eTucaxen 150 mg Tablet\u003c\/strong\u003e contains \u003cstrong\u003etucatinib 150 mg\u003c\/strong\u003e, a targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. It works by selectively blocking \u003cstrong\u003eHER2 signaling\u003c\/strong\u003e, which helps slow or stop the growth and spread of HER2-positive cancer cells. Tucaxen is mainly used in combination with \u003cstrong\u003etrastuzumab and capecitabine\u003c\/strong\u003e for adults with \u003cstrong\u003eHER2-positive unresectable locally advanced or metastatic breast cancer\u003c\/strong\u003e, including patients with brain metastases. It is an oral film-coated tablet and should be taken strictly according to an oncologist’s prescription. Common side effects may include \u003cstrong\u003ediarrhea, nausea, vomiting, fatigue, rash, and increased liver enzymes\u003c\/strong\u003e.\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44898302459947,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Tucaxen.png?v=1787344672"},{"product_id":"talaparib-1mg-talazoparib","title":"Talaparib 1mg (Talazoparib)","description":"\u003cp\u003e\u003cstrong\u003eTalaparib 1 mg (Talazoparib)\u003c\/strong\u003e is an oral targeted anticancer medicine belonging to the \u003cstrong\u003ePARP inhibitor\u003c\/strong\u003e class. It works by blocking PARP enzymes involved in DNA repair, which can cause certain cancer cells to die. It is primarily used for treating \u003cstrong\u003eHER2-negative breast cancer with specific BRCA gene mutations\u003c\/strong\u003e and may be prescribed for other approved indications depending on the patient and country. Talaparib should be used under the supervision of an oncologist.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTherapeutic class:\u003c\/strong\u003e PARP inhibitor \/ targeted anticancer therapy.\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44898312093739,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Talaparib.png?v=1787345742"},{"product_id":"olanib-150olaparib-inn-150-mg","title":"Olanib 150(Olaparib INN 150 mg)","description":"\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eOlanib 150\u003c\/strong\u003e contains \u003cstrong\u003eolaparib 150 mg\u003c\/strong\u003e and is manufactured by Everest Pharmaceuticals in Bangladesh. It is an \u003cstrong\u003eoral targeted cancer medicine\u003c\/strong\u003e belonging to the \u003cstrong\u003ePARP inhibitor\u003c\/strong\u003e class.\u003c\/p\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003eOlaparib works by blocking PARP proteins involved in DNA repair. This can make it difficult for certain cancer cells—especially those with \u003cstrong\u003eBRCA or other DNA-repair abnormalities\u003c\/strong\u003e—to survive. It is used for selected patients with \u003cstrong\u003eovarian, breast, pancreatic, and prostate cancers\u003c\/strong\u003e, depending on the cancer type and genetic\/biomarker results. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImportant:\u003c\/strong\u003e Olanib 150 should be taken \u003cstrong\u003eonly under an oncologist's prescription\u003c\/strong\u003e. The 150 mg tablet is not necessarily the dose every patient should take; the usual tablet regimen for many indications is \u003cstrong\u003e300 mg twice daily\u003c\/strong\u003e, but the correct dose depends on the patient and cancer.\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":45022305976363,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Olanib150_4d868bfe-e2d1-470c-878c-3f2e917cc2fa.jpg?v=1787512662"},{"product_id":"alpesib-150mg-tablet-alpelisib","title":"Alpesib 150mg tablet (alpelisib)","description":"\u003cp\u003e\u003cstrong\u003eAlpesib 150 mg\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anticancer medicine manufactured by \u003c\/span\u003e\u003cstrong\u003eEverest Pharmaceuticals Ltd., Bangladesh\u003c\/strong\u003e\u003cspan\u003e. Each film-coated tablet contains \u003c\/span\u003e\u003cstrong\u003eAlpelisib 150 mg\u003c\/strong\u003e\u003cspan\u003e, a selective phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant activity against PI3K-alpha. It is used in combination with \u003c\/span\u003e\u003cstrong\u003efulvestrant\u003c\/strong\u003e\u003cspan\u003e for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), HER2-negative, \u003c\/span\u003e\u003cstrong\u003ePIK3CA-mutated advanced or metastatic breast cancer\u003c\/strong\u003e\u003cspan\u003e following progression on or after endocrine-based therapy. Alpelisib works by inhibiting abnormal PI3K\/AKT signaling associated with PIK3CA mutations, helping to slow the growth of cancer cells. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe recommended dose is \u003cstrong\u003e300 mg once daily with food\u003c\/strong\u003e, which corresponds to two 150 mg tablets, although dose reductions may be required depending on tolerability and adverse reactions. Important treatment-related risks include \u003cstrong\u003ehyperglycemia, diarrhea, rash, and pneumonitis\u003c\/strong\u003e, so treatment requires appropriate medical monitoring.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":45104551362603,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Alpesib.jpg?v=1787575705"}],"url":"https:\/\/xomeds.com\/collections\/breast-cancer.oembed","provider":"XOMEDS","version":"1.0","type":"link"}